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Abstract
Background: The multiple wavelets and functional re‐entry hypotheses are
mechanistic theories to explain atrial fibrillation (AF). If valid, a chamber's ability to
support AF should depend upon the left atrial size, conduction velocity (CV), and
refractoriness. Measurement of these parameters could provide a new therapeutic
target for AF. We investigated the relationship between left atrial effective
conducting size (LAECS), a function of area, CV and refractoriness, and AF
vulnerability in patients undergoing AF ablation.
Methods and Results: Activation mapping was performed in patients with
paroxysmal (n = 21) and persistent AF (n = 18) undergoing pulmonary vein isolation.
Parameters used for calculating LAECS were: (a) left atrial body area (A); (b) effective
refractory period (ERP); and (c) total activation time (T). Global CV was estimated as
√ /A T . Effective atrial conducting size was calculated as = /( × )LA A CV ERPECS . Post
ablation, AF inducibility testing was performed. The critical LAECS required for
multiple wavelet termination was determined from computational modeling. LAECS
was greater in patients with persistent vs paroxysmal AF (4.4 ± 2.0 cm vs 3.2 ± 1.4 cm;
P = .049). AF was inducible in 14/39 patients. LAECS was greater in AF‐inducible
patients (4.4 ± 1.8 cm vs 3.3 ± 1.7 cm; P = .035, respectively). The difference in LAECS
between inducible and noninducible patients was significant in patients with
persistent (P = .0046) but not paroxysmal AF (P = .6359). Computational modeling
confirmed that LAECS > 4 cm was required for continuation of AF.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Steven E Williams and Louisa O’Neill contributed equally to this study.
Conclusions: LAECS measured post ablation was associated with AF inducibility in
patients with persistent, but not paroxysmal AF. These data support a role for this
method in electrical substrate assessment in AF patients.
K E YWORD S
atrial fibrillation vulnerability, conduction velocity, left atrial effective conducting size,
refractoriness
1 | INTRODUCTION
The multiple wavelet hypothesis, initially proposed by Moe et al1 in
the 1950s, is an established mechanistic theory to explain the
maintenance of atrial fibrillation (AF). According to this theory,
sustained fibrillatory activity is the result of multiple random
independent wavefronts propagating across an altered electrical
substrate which maintain fibrillation after the initial trigger is
extinguished. Support for the multiple wavelet hypothesis was
originally demonstrated in a canine model of cholinergic AF,2 but
more recently both electrocardiographic imaging during AF in
patients with paroxysmal, persistent and long‐standing persistent
AF,3 and epicardial mapping in patients with persistent AF under-
going open heart surgery4 have further supported this mechanism in
human AF.
Another important mechanistic theory of AF, that of “functional
re‐entry,” was proposed by Allessie et al5 in an ex vivo study of rabbit
atria. In this study, rotating re‐entry occurred in the absence of an
anatomical obstacle. Subsequent studies further demonstrated
functional, anatomic, and micro re‐entry to be driving mechanisms
in animal models of AF.6,7 In the modern era two new technologies
(intracardiac phase mapping8 and electrocardiographic imaging9)
have also been used to demonstrate, albeit controversially, the
occurrence of rotors in human AF, described previously as drivers of
function re‐entry.10
Since directly mapping activation in AF is challenging, our ability
to deliver therapies based on such mechanisms is currently limited.
Nevertheless, a key concept of these hypotheses is that a critical
mass of tissue is required to facilitate the perpetuation of AF.11
Whether chamber size determines the capacity of the chamber to
sustain multiple re‐entrant wavelets will depend on the electrical
properties (conduction velocity [CV] and refractoriness) of that
chamber.12 A technique to quantify the electrical substrate size of an
atrium, based on a limited set of measurements collectible within a
clinically applicable timescale, would allow interventional AF treat-
ments to be individualized. We therefore propose a metric termed
“Effective Conducting Size” (units, cm) which is a function of total
atrial area, CV, and a single‐site measurement of refractoriness. We
hypothesize that the ability of a chamber to support AF is related to
Effective Conducting Size, independent of the use of antiarrhythmic
medication.
2 | MATERIALS AND METHODS
2.1 | Patient selection and clinical procedures
Adult patients with AF undergoing first‐time ablation were eligible for
inclusion. The research protocol conformed to principles outlined in the
Declaration of Helsinki and ethical approval was granted by the National
Research Ethics Service. Written informed consent was obtained from all
participants before the study. Patients with prior atrial ablation were
excluded. Following femoral venous access, a decapolar (St. Jude Medical,
St. Paul, Minnesota) catheter was positioned in the coronary sinus. Left
atrial access was obtained via a trans‐femoral approach following a trans‐
septal puncture. A circular mapping catheter (Lasso; Biosense Webster,
Diamond Bar, CA) and an 8Fr ablation catheter (Thermocool, Smart-
Touch; Biosense Webster) were advanced into the left atrium via two
8.5Fr SR0 sheaths. All patients were anticoagulated intraprocedurally
targeting an activated clotting time of >300milliseconds.
2.2 | Left atrial mapping and pacing protocol
Before ablation, all patients underwent left atrial activation and voltage
mapping using the Carto electro‐anatomic mapping system (Biosense
Webster, Diamond Bar, CA) during coronary sinus pacing at a cycle
length of 600milliseconds. For patients who presented in AF, direct
current cardioversion was performed. Wide‐area encirclement of the
pulmonary veins was performed in power‐controlled mode using a
contact force‐sensing ablation catheter. Entrance and exit block were
demonstrated to confirm pulmonary vein isolation and additional ablation
performed in the case of reconnection. Following successful pulmonary
vein isolation, the ablation catheter was positioned in the center of the
posterior left atrial wall. Once adequate contact force (>3 g) and catheter
stability were achieved, a pacing protocol was applied consisting of an
8‐beat drive train at a basic cycle length (BCL) of 600milliseconds and an
extra stimulus with coupling intervals reducing from 450milliseconds in
10millisecond steps. The atrial effective refractory period (ERP) was
defined as the longest extra stimulus coupling interval failing to capture
the atrium.
2.3 | AF vulnerability
Following ERP measurements, an AF induction protocol was
performed by pacing from the ablation catheter at the left atrial
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posterior wall. The protocol consisted of sensed doubles (S1 = 600
milliseconds; S2 = 400milliseconds, decreasing in 10milliseconds
steps to atrial ERP), sensed triples S1 = 600milliseconds; S2 =ERP +
50 milliseconds, S3 =ERP + 50 milliseconds, decreasing in 10milli-
second steps to atrial ERP) and incremental pacing, decreasing in
10millisecond intervals from 450milliseconds to loss of 1:1 atrial
capture.13 Each step in the induction protocol was carried out once
before moving onto the subsequent step. If AF was not induced by
this protocol the entire protocol was repeated for a second time.
Sustained AF was defined as AF continuing for greater than
30 seconds. If AF resolved to an organized tachycardia, overdrive
pacing was used to terminate the tachycardia. Sustained AF was
terminated by electrical cardioversion if required.
2.4 | Calculation of LAECS
Carto3 maps were analyzed offline and used to calculate left atrial
body atrial area, total activation time, and global CV. Left atrial body
area (A) was calculated by subtracting the area of the isolated
pulmonary veins, the left atrial appendage, and the mitral annulus
from the total area of the left atrial shell (Figure 1). Total activation
time (T) was calculated by subtracting the earliest from the latest
activation time point as annotated on the isochronal activation maps.
Using A and T as the characteristic length and time, respectively,
we defined the characteristic CV as
= A
T
CV
Wavelength was defined as the shortest circuit that can sustain
re‐entry and was calculated as
λ = ×CV ERP
Left atrial effective conducting size (LAECS, units = cm) was then
calculated as
λ=LA
A
ECS
2.5 | Atrial multiple wavelets model
Two dimensional (2D) and three dimensional (3D) computational
modeling. For the 2D model, an 11 × 10 cm atrial tissue model was
meshed using quadrilateral elements (1,100,000 elements, 1,102,101
nodes, average edge length Δl= 0.1 mm). Electrical propagation was
modeled using the mono‐domain equation, with isotropic conductiv-
ities of 0.3 S/m, giving CV= 77 cm/s. The cellular ionic current was
modeled using the Luo‐Rudy cellular model, with ionic conductances
modified to reproduce atrial cellular properties following Virag et al
(GNa = 16mS/cm
2, GK = 0.423mS/cm
2, and GSi = 0.085mS/cm
2).14,15
AF is sustained in this model by multiple wavelets undergoing
functional re‐entry and wave break.15 The ionic conductance of IK1
was modified to reproduce the average ERP of the inducible
persistent AF patients in this study (GK1 = 1.8 mS/cm
2), to attain
ERP = 231milliseconds. AF was initiated by cross‐field stimulation.
The numerical simulations were performed with CARPentry (https://
carp.medunigraz.at/carputils/). To model the effects of pulmonary
vein isolation, tissue at the left and right‐hand edges of the domain
were set to be nonconductive (0.001 S/m). The effect of reducing left
atrial body area by 10 to 60 cm2 was modeled by setting between 0.5
to 3.0 cm at each side of the domain to be nonconductive. To model
the effects of changes in ERP (for example by the administration of
sotalol), IK1 conductance was modified. Following Mitchell et al, we
modeled ERP prolongation by sotalol in the range 290 to 330milli-
seconds.16
3D simulations were performed on three left atrial anatomies
generated from cardiac magnetic resonance sequences represent-
ing a range of left atrial body surface areas: 75, 103, and 140 cm2.
The pulmonary veins were clipped (https://www.paraview.org) and
meshes created using MMG tools software (http://www.mmgtools.
org/). Endocardial atrial fiber direction information was mapped
from an atlas geometry,17 and modeled with longitudinal con-
ductivity 0.4 S/m and transverse conductivity 0.1 S/m (resultant
CV = 0.77 m/s). As for the 2D simulations, sotalol administration
was modeled by varying the ionic conductance of IK1 to produce
ERP values in the range of 230 to 270 milliseconds. Ablation was
modeled during arrhythmia simulations by setting ablation region
conductivities as nonconductive (0.001 S/m). The following ablation
patterns were applied: (a) pulmonary vein isolation alone via wide‐
area encirclement of the pulmonary veins and (b) pulmonary vein
isolation together with roof and inferior lines to model posterior
wall box isolation. To vary the area of the isolated tissue the
F IGURE 1 Estimation of post‐ablation LA body area and the
typical site for ERP measurement. LA body area was calculated from
Carto shells by subtracting the area of the isolated pulmonary veins
(shaded), the left atrial appendage, and the mitral annulus from the
total area of the LA shell. The yellow tag indicates the site at which
ERP measurements and AF induction protocol were performed. The
activation map was recorded during coronary sinus pacing. AF, atrial
fibrillation; ERP, effective refractory period; LA, left atrial
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inferior line was applied at increasingly inferior locations on the
posterior wall.
2.6 | Statistical analysis
Data analysis were performed using SPSS statistics (IBM, Version
22) and Prism (GraphPad Software, Version 7). Continuous
variables were expressed as a mean ± standard deviation. Compar-
ison of means between groups was performed using the Mann‐
Whitney U test for independent samples. Categorical variables
were compared using χ2 test. P < .05 was considered statistically
significant.
3 | RESULTS
3.1 | Demographics and procedural details
Thirty‐nine patients (21 paroxysmal AF, 18 persistent AF) undergoing
first‐time AF ablation were studied (Table 1). Mean AF history was
28 ± 37.4 months. Thirty patients were receiving rate‐controlling agents
periprocedurally (β‐blockers n = 26; verapamil n = 3, digoxin n = 3) and
16 were taking antiarrhythmic medications (amiodarone n = 4; flecai-
nide n = 10, others n = 2). Sustained AF was inducible in 14 (36%)
patients overall (7 paroxysmal AF, 7 persistent AF).
3.2 | Measured parameters and calculated
parameters
Mean left atrial body area was 86.1 ± 18.8 cm2. Mean ERP
(BCL = 600 milliseconds) was 262.6 ± 57.2 milliseconds. Mean left
atrial total activation time was 97.1 ± 27.7 milliseconds. Calculated
mean CV was 1.0 ± 0.4 m/s. Calculated mean LAECS was
3.7 ± 1.8 cm (Table 1).
3.2.1 | Category of AF
LAECS was significantly greater in patients with persistent AF than
paroxysmal AF (4.4 ± 2.0 cm vs 3.2 ± 1.4 cm; P = .049; Figure 2) owing
to a significantly greater left atrial body area in persistent AF
patients (98.6 ± 18.0 cm2 vs 75.3 ± 11.6 cm2; P < .001). Left atrial total
activation time was significantly longer in patients with persistent AF
than paroxysmal AF (109 ± 30milliseconds vs 87 ± 21milliseconds;
P = .005) but there were no significant relationships between ERP
(266 ± 67milliseconds vs 260 ± 48milliseconds; P = .667), CV
(1.0 ± 0.6m/s vs 1.0 ±;0.2 m/s; P = .14) or wavelength (27 ± 11.7 cm
vs 27 ± 7.8 cm; P = .707) and AF category.
3.2.2 | AF vulnerability
Overall, LAECS was significantly greater in patients in whom AF was
inducible than patients in whom AF was not inducible (4.4 ± 1.8 cm vs
3.3 ± 1.7 cm; P = .035; Figure 3). Left atrial body area was significantly
greater in AF‐inducible patients than in noninducible patients
(95.5 ± 19.6 cm2 vs 80.7 ± 16.4 cm2; P = .0167) but there were no
significant relationships between ERP (245 ± 56milliseconds vs
272 ± 56milliseconds; P = .118), CV (1.0 ± 0.2 m/s vs 1.1 ±;0.5 m/s;
P = .784) or wavelength (24.2 ± 7.9 cm vs 28.4 ± 9.8 cm; P = .141) and
AF inducibility. There was no significant relationship between AF
type and ability to induce AF (paroxysmal AF 33.3% inducible vs
67.7% noninducible; persistent AF 38.9% inducible vs 61.1%
noninducible; P = .718).
3.2.3 | AF vulnerability according to AF type
Left atrial body area was significantly greater (109.1 ± 15.9 cm2 vs
91.9 ± 16.4 cm2; P = .0346) and wavelength was significantly shorter
(20.3 ± 4.8 cm vs 30.9 ± 13.1 cm; P = .0441) for persistent AF cases
who were inducible compared to those who were noninducible
TABLE 1 Summary of population demographics and measured and calculated study parameters according to AF category and AF
vulnerability
AF category AF vulnerability
Parameter PAF PsAF P Non‐inducible Inducible P
Age, y 56.2 ± 11.5 65.6 ± 15.1 .004 61.4 ± 13 59.1 ± 15.8 .817
Male sex, % 61.9 72.2 .337 62.5 78.6 .304
Paroxysmal AF, % n/a n/a n/a 56 50 .718
Rate control, % 71.4 83.3 .379 76 78.6 .855
Rhythm control, % 52.4 27.8 .119 40 42.9 .862
LA body area, cm2 75.3 ± 11.6 98.6 ± 18 <.001 80.7 ± 16.4 95.5 ± 19.6 .0167
ERP, ms 259.5 ± 48.2 266.1 ± 67.4 .667 272.4 ± 56.7 245 ± 55.7 .118
CV, m/s 1.0 ± 0.2 1.0 ± 0.6 .140 1.1 ±;0.5 1.0 ± 0.2 .784
λ, cm 27 ± 7.8 27 ± 11.7 .707 28.4 ± 9.8 24.2 ± 7.9 .141
LAECS, cm 3.2 ± 1.4 4.4 ± 2.0 .049 3.3 ± 1.7 4.4 ± 1.8 .035
Abbreviations: AF, atrial fibrillation; CV, conduction velocity; ERP, effective refractory period; LA, left atrium; LAECS, left atrial effective conducting size;
PAF, paroxysmal AF; PsAF, persistent AF; λ, wavelength.
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(Figure 4). The significant relationship between LAECS and AF
inducibility was driven by persistent AF (5.6 ± 1.4 cm vs 3.6 ±;2 cm;
P = .0046) but not paroxysmal AF (3.2 ± 1.1 cm vs 2.1 ± 1.5 cm;
P = .6359) cases. Wavelength is plotted against left atrial body area
in Figure 5. Patients with paroxysmal AF who were both inducible
and noninducible localized between the 2 to 4 cm LAECS isolines. In
contrast, patients with persistent AF who were inducibly localized
below the 4 cm isoline (ie LAECS > 4 cm).
3.2.4 | Simulated data
2D simulations
Baseline parameter sets were chosen to model multiple wavelet re‐entry
with the ERP tuned to match the mean value for the inducible persistent
AF patients. AF was sustained for this set‐up (Figure 6A) with a calculated
LAECS = 6.18 cm (filled hexagon; Figure 6D). The effects of ablation and
antiarrhythmic drugs on arrhythmia inducibility were tested by altering
the conducting area of the domain and IK1 channel conductance,
respectively. When atrial area was modified by ablation, a critical
LAECS > 4 cm was required for maintenance of AF. AF was sustained for
atrial areas of 80 cm2 (LAECS = 4.5 cm, filled circle; Figure 6D) or larger,
whilst reducing the atrial area to 70 cm2 (LAECS = 3.9 cm; empty circle;
Figure 6D) resulted in AF termination (Figure 6B). When modifications in
ERP and CV were modeled by the application of sotalol, a critical
LAECS > 4 cm was still required for maintenance of AF. AF was sustained
at an ERP of 290milliseconds (LAECS = 4.6; filled triangle; Figure 6D), but
not at an ERP of 320milliseconds (LAECS = 4 cm; empty triangle; Figure
6D) (Figure 6C). Modifying ERP through changes in GK1 conductance also
modified CV, such that CV=86 cm/s at ERP=320milliseconds and
CV=83 cm/s at ERP=290milliseconds.
F IGURE 2 LA body area, calculated wavelength, and effective conducting size in patients with paroxysmal and persistent AF. A, LA body
area was significantly greater in patients with persistent AF than paroxysmal AF. B, There was no significant difference in the calculated
wavelength between patients with paroxysmal and persistent AF. C, Effective conducting size was significantly greater in patients with
persistent than paroxysmal AF. AF, atrial fibrillation; LA, left atrium; LAECS, LA effective conducting size; PAF, paroxysmal AF; PsAF, persistent
AF
F IGURE 3 LA body area, calculated wavelength, and effective conducting size in patients with and without inducible AF. A, LA body area was
significantly greater in patients with inducible vs. noninducible AF. B, There was no significant difference in wavelength between patients who
were and were not AF inducible. C, Effective conducting size was significantly greater in patients with inducible vs noninducible AF. AF, atrial
fibrillation; LA, left atrium; LAECS, LA effective conducting size; PAF, paroxysmal AF; PsAF, persistent AF
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3D simulations
For the smallest geometry, ERP values of 250 to 270milliseconds
resulted in LAECS < 4 cm and for these simulations arrhythmias were
not sustained (Figure 7A); whereas in simulations with an ERP of
either 230milliseconds (LAECS = 4.23 cm) or 240milliseconds
(LAECS = 4.06 cm; Figure 7B) AF was sustained. In comparison, for
both the medium and large anatomies, ERPs between 230 and
270milliseconds all resulted in LAECS > 4 cm and AF was correspond-
ingly sustained in all cases (Figure 7C,D). Figure 7E shows LAECS, ERP,
and left atrial body area for inducible and noninducible cases. The
median LAECS for noninducible cases is 3.85 cm, compared to 5.52 cm
for inducible cases (P < .0001). The median ERP and area values are
also significantly different between inducible and noninducible cases.
In 76% of the simulations, AF sustained after pulmonary vein
isolation (Figure 8A). Applying a box isolation lesion set further
reduced LAECS and terminated AF in 67% of simulation set‐ups using
the inferior line that resulted in the lowest LAECS. Figure 8B shows an
example in which AF was inducible with the smallest area of isolated
tissue owing to a resultant atrial area of 121 cm2 and corresponding
LAECS of 5.82 cm. Figure 8C shows the same anatomy, ERP and CV
properties as Figure 8B. In this case, increasing the area of the
isolated posterior box resulted in a LAECS of 3.94 cm, and termination
of AF. In contrast, Figure 8D demonstrates a case in which AF is still
inducible following the largest box isolation lesion set with an ERP of
230milliseconds and LAECS remaining above 4 cm (LAECS = 4.18 cm).
By additionally increasing ERP to 250milliseconds, through modeling
the effects of sotalol, LAECS is decreased less than 4 cm (LAECS =
3.84 cm) and AF terminates (Figure 8E).
4 | DISCUSSION
In this study, we sought to design and test a clinically applicable
technique to quantify atrial electrical substrate size determined using an
atrial activation map and a single measurement of ERP. The main finding
of the study is that LAECS is significantly greater in persistent, but not
paroxysmal, AF patients who remain AF inducible after ablation. A critical
LAECS > 4 cm is associated with inducibility of AF in both persistent AF
patients and in 2‐ and 3‐dimensional simulation studies. Simulation
studies also indicate that a combination of ablation and antiarrhythmic
F IGURE 4 LA body area, calculated wavelength, and effective conducting size in patients with and without inducible AF, by AF class. There
was no significant difference in LA body area (A), wavelength (B) or left atrial effective conducting size (C) between paroxysmal AF cases who
were and were not AF inducible. LA body area (D) and left atrial effective conducting size (F) was significantly greater, and calculated
wavelength (E) was significantly smaller in persistent AF cases who were AF inducible compared to those who were not AF inducible. AF, atrial
fibrillation; LA, left atrium; LAECS, LA effective conducting size; PAF, paroxysmal AF; PsAF, persistent AF
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drugs may be required to reduce LAECS to <4 cm in certain patients.
These findings support a future role for LAECS in guiding interventional,
pharmacological or combined therapies for persistent AF.
4.1 | Atrial size, electrical remodeling, and AF
vulnerability
Left atrial dilatation is a well‐described risk factor for the develop-
ment of AF and is associated with disease severity and outcome post
ablation.18 These data demonstrate that left atrial body area is
significantly associated with both AF severity (persistent vs
paroxysmal AF) and AF vulnerability in persistent AF cases. The
mechanisms by which atrial dilatation may increase AF vulnerability
are incompletely understood. According to the multiple wavelet
hypothesis, an increased atrial area would allow more re‐entrant
circuits to exist1,19 and thus increase susceptibility to AF. However,
alterations in electrical properties could also be associated with atrial
dilatation and contribute to the maintenance of AF.
Prior studies assessing the relationship between electrical
remodeling and atrial dilatation have, however, yielded inconsistent
results. Ravelli et al20 demonstrated shortened refractory periods in
association with high atrial pressures in isolated rabbit atria.
Conversely, Sparks et al21 demonstrated increased refractory
periods in patients with chronic VVI pacing and increased atrial
dimensions. Conduction slowing and block have been associated with
acute dilatation in isolated rabbit atria22 and an association between
reduced CV, atrial dilation, and arrhythmias has also been shown in
human studies.23 In the present study, we found no significant
relationship between left atrial size and ERP or total activation time
in patients with either paroxysmal and persistent AF, although a
nonsignificant trend toward shorter ERP and longer total activation
time were noted in persistent patients with inducible vs noninducible
AF. Therefore, there is a need to consider both atrial size and
electrical conduction together (for example using LAECS) in individual
patients to predict response to treatments for arrhythmias.
4.2 | The concept of Re‐entry, wavelength, and
atrial substrate size
The concept of “atrial substrate size” was originally communicated by
Moe in terms of a dimensionless quantity termed the fibrillation
number.19 In a study by Hwang et al,24 fibrillation number, a function of
wavelength and atrial diameter measured on 2D echo, was shown to be
related to AF duration in computer simulations and AF induction cycle
length in patients with AF undergoing ablation. Similarly, in an in vivo
study in swine Lee et al25 demonstrated that the probability of
sustained AF increased significantly with increasing tissue area and
decreasing ERP. Wavelength, incorporating both refractory period and
CV, has been shown to be a key determinant of re‐entry5 reliably
predicting arrhythmia vulnerability in a canine study.26
Given the interaction between atrial size, refractoriness, CV, and AF
vulnerability, we incorporated these parameters into a new metric
termed LAECS. This metric differs from the fibrillation number previously
described19,24 by using atrial surface area rather than a characteristic
length constant such as atrial diameter which we believe is likely to
better capture the complex geometrical remodeling present in AF
patients.27 We extended the above findings to a population of AF
patients by demonstrating that wavelength is significantly shorter and
LAECS significantly greater in persistent AF patients with inducible vs
noninducible AF (Figure 4F). LAECS also notably identified a population of
patients with persistent AF who were not AF‐inducible after PVI and
who, from an electrophysiological standpoint, appear to behave more like
paroxysmal AF patients. Although this parameter ignores heterogeneity
F IGURE 5 Relationship between induction of AF and LA body
area, calculated wavelength and effective conducting size. A, LA body
area is plotted on the x‐axis and calculated wavelength (see text) on
the y‐axis for all patients in the study. B, Isolines represent LAECS.
Patients with paroxysmal AF who were both AF inducible (D) and AF
noninducible (C) localized around the 2 to 4 cm LAECS region
(shaded). Patients with persistent AF who were noninducible
occupied a larger range of effective conducting size from 1.3 to
10 cm (E). Patients with persistent AF who were AF inducible largely
fell within the >4 cm range for LAECS. AF, atrial fibrillation; LA, left
atrium; LAECS , LA effective conducting size; PAF, paroxysmal AF;
PsAF, persistent AF
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in refractoriness,28 quantifying such heterogeneity is time‐consuming and
therefore not easily translated from research to clinical settings.
Conversely, the data set required for calculation of LAECS in this study
is easily obtainable within the timeframe of an ablation procedure and
according to the present data is likely to represent a useful and clinically
applicable metric for assessing AF vulnerability irrespective of the clinical
AF categorization.
4.3 | Clinical relevance
This study highlights the physiological difference between categories
of AF and suggests a possible methodology by which arrhythmia
management strategies could be individualized for patients post‐
pulmonary vein isolation. In patients with LAECS < 4 cm, a trigger‐based
ablation strategy may be most appropriate. In this study, LAECS < 4 cm
F IGURE 6 Effect of ablation and antiarrhythmic drugs on effective conducting size. Computational modeling confirmed that a critical
LAECS > 4 cm was required for sustained multiple wavelet re‐entry. A, Re‐entry was sustained with LAECS = 6.18 cm (hexagon in “D”). B, Effect of
reducing the atrial area to 80 cm2 (top row, continued AF, LAECS = 4.5 cm, closed circle in D) and 70 cm
2 (bottom row, AF termination,
LAECS = 3.94 cm, open circle in D). C, Effect of increasing sotalol doses on LAECS. AF continued when LAECS > 4 cm (top row, closed triangle in D)
but terminated with LAECS = 4.0 cm (bottom row, open triangle in D). D, Illustrates how ablation or antiarrhythmic drugs could be applied to
alter LAECS and remove patients from the region of vulnerability (shaded grey). Ablation would reduce left atrial body area with a corresponding
reduction in LAECS (red arrow). Conversely, antiarrhythmic drugs to prolong refractoriness could be applied to increase LA wavelength (green
arrow) and decrease LAECS. AF, atrial fibrillation; LAECS , LA effective conducting size
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F IGURE 7 Effect of left atrial effective conducting size on arrhythmia inducibility in patient‐specific simulations. A, For the smallest anatomy
(area 75 cm2), AF is noninducible for an ERP value of 250milliseconds and LAECS = 3.90 cm. Isopotential plots are shown for time points at
250milliseconds intervals. B, For the same anatomy as “A”, AF is inducible for an ERP value of 240milliseconds and LAECS = 4.06 cm. C, For the
medium anatomy (area 103 cm2), AF is inducible for a longer ERP (270milliseconds) than for the smallest anatomy shown in “B”. D, For the
largest anatomy (area 140 cm2), AF is inducible for all tested values of ERP. The example here is for an ERP of 250milliseconds (as in “A”) and
LAECS = 7.27 cm. E, LAECS, left atrial body area and ERP are shown for inducible and noninducible simulations. Median LAECS is significantly
lower for noninducible cases (3.85 cm vs 5.52 cm; P < .001), median left atrial body area is significantly lower for noninducible cases (75 cm2 vs
103 cm2; P < .001) and median ERP is significantly higher for noninducible cases (260milliseconds vs 240milliseconds; P < .001). AF, atrial
fibrillation; ERP, effective refractory period; LAECS , LA effective conducting size
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incorporated the vast majority of patients with paroxysmal AF which is
in line with success rates of pulmonary vein isolation in this
population.29 Notably, however, even persistent AF patients with
LAECS < 4 cm were noninducible after pulmonary vein isolation,
suggesting that isolation of PV triggers could be successful in this
subpopulation. Conversely, in patients with LAECS > 4 cm, additional
substrate modification is likely to be required. In these patients, initial
trigger‐dependent AF may have evolved to multiple wavelet/re‐entry
based AF due to progressive structural and electrical remodeling.30 In
recent years, additional catheter ablation strategies have been
suggested in persistent AF patients31-33, however, the optimal
treatment approach remains unclear.34 According to the present data
targeted strategies to reduce LAECS (Figures 6D and 8) may improve
the success of rhythm control strategies. In contemporary practice, a
reduction in LAECS could be achieved by positioning the PV wide‐area
encirclement lines more toward the center of the chamber, by isolating
F IGURE 8 Left atrial effective size‐based arrhythmia therapy insights from patient‐specific simulations. A, AF is inducible post‐pulmonary
vein isolation for the largest anatomy (area 140 cm2) with an ERP of 270milliseconds (LAECS = 6.73 cm). Isopotential plots are shown for time
points at 250milliseconds intervals. B, AF is inducible after applying the smallest box isolation ablation to the largest anatomy (remaining left
atrial body area, 121 cm2) with an ERP of 270milliseconds (LAECS = 5.82 cm). C, AF is noninducible after applying the largest box isolation
ablation to the largest anatomy (remaining left atrial body area, 82 cm2) with an ERP of 270milliseconds (LAECS = 3.94 cm). Together “B” and “C”
show that reducing the remaining left atrial body area is a viable therapeutic strategy to reduce LAECS and AF inducibility. D, AF is inducible
after applying the largest box isolation ablation to the medium anatomy (remaining left atrial body area, 74 cm2) with an ERP of
230milliseconds (LAECS = 4.18 cm). E, Modifying the ERP to 250milliseconds for the case in “D” results in non‐inducibility (LAECS = 3.84 cm).
Together “D” and “E” show that in certain cases combined the use of ablation and antiarrhythmic drugs may be needed to achieve the necessary
reduction in LAECS and prevent AF inducibility. Dotted red lines indicate ablation lesion trajectories. “A”‐“C” (largest anatomy) are shown in
posteroanterior orientation. D‐E, (medium anatomy) are shown in anteroposterior orientation with cranial tilt. AF, atrial fibrillation; ERP,
effective refractory period; LAECS, LA effective conducting size
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the LA posterior wall35 or by the selective use of antiarrhythmic drugs
to prolong atrial refractoriness. Our modeling data highlights how in
certain cases even a large posterior box isolation set does not reduce
the LAECS sufficiently to terminate AF and this is only achieved
through an additional increase in ERP. As such, knowledge of LAECS
could be used to guide ablation during the initial ablation procedure or
to guide the selection of additional ablation vs. antiarrhythmic drugs
for the management of recurrent arrhythmia after initial ablation. Such
management strategies require investigation in prospective rando-
mized trials.
5 | LIMITATIONS
This was a prospective simulation/clinical study to evaluate a new
clinically applicable concept. Since there were a low number of
recurrence events in the cohort, it was not possible to formally
test the predictive power of LAECS in a statistical model including
other clinical parameters associated with AF vulnerability and
recurrence. ERP was measured at a single site in the left atrium
which may not be fully reflective of the heterogeneity in
refractoriness seen in patients with persistent AF. Some patients
were maintained on antiarrhythmic drugs periprocedurally. While
the effects of these in terms of CV and refractoriness will be
accounted for in the LAECS concept, it is not possible to predict
how discontinuation of medications post procedure may affect the
vulnerability to AF in a particular patient from these data.
Therefore, LAECS measured in the study may not reflect the true
LAECS once antiarrhythmic drugs are either discontinued or
resumed post procedure. This study focused on multiple wavelet
mechanisms of AF only. It is possible that this hypothesis may hold
for other forms of re‐entry in including micro‐entrant circuits and
rotors however this was not explored in the modeling work carried
out here. Similarly, we did not examine the potential roles of the
right atrium in arrhythmogenesis in these patients.
6 | CONCLUSION
LAECS was significantly associated with the ability to induce AF in
patients post first‐time ablation for persistent, but not paroxysmal
AF. These data support the mechanistic hypotheses of re‐entry in the
population of persistent AF patients studied. The LAECS metric may
be useful for predicting AF vulnerability and guiding arrhythmia
management in such patients.
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